Global X Genomics & Biotechnology ETF holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
Global X Genomics & Biotechnology ETF GNOM
Morningstar’s Analysis GNOM
Will GNOM outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 55.7
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Moderna Inc | 9.45 | 10M | Healthcare |
Twist Bioscience Corp | 8.10 | 8M | Healthcare |
10x Genomics Inc Ordinary Shares - Class A | 7.28 | 7M | Healthcare |
Illumina Inc | 5.72 | 6M | Healthcare |
Guardant Health Inc | 5.43 | 6M | Healthcare |
Natera Inc | 5.43 | 6M | Healthcare |
Genscript Biotech Corp Class H | 4.63 | 5M | Healthcare |
Bio-Techne Corp | 3.38 | 3M | Healthcare |
Vertex Pharmaceuticals Inc | 3.26 | 3M | Healthcare |
BioMarin Pharmaceutical Inc | 3.02 | 3M | Healthcare |